The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 10, 2021

Filed:

Mar. 12, 2014
Applicants:

The General Hospital Corporation, Boston, MA (US);

Massachusetts Eye and Ear Infirmary, Boston, MA (US);

Inventors:

Patricia K. Donahoe, Boston, MA (US);

Demetrios Vavvas, Boston, MA (US);

David Pepin, Somerville, MA (US);

Mien Van Hoang, Braintree, MA (US);

Assignees:
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61K 38/22 (2006.01); C07K 14/765 (2006.01); C07K 14/575 (2006.01); A61P 15/08 (2006.01); A61P 5/28 (2006.01); A61K 45/06 (2006.01); A61K 31/416 (2006.01);
U.S. Cl.
CPC ...
C07K 14/575 (2013.01); A61K 31/416 (2013.01); A61K 45/06 (2013.01); C07K 14/765 (2013.01); A61K 38/00 (2013.01); C07K 2319/43 (2013.01); C07K 2319/50 (2013.01); Y02A 50/30 (2018.01);
Abstract

The present invention relates to modified recombinant human MIS protein which has improved cleavage and increased bioactivity and increased potency as compared to wild-type human MIS protein. Other aspects of the invention relate to methods to prevent and treat cancers, such as cancers that express the MIS receptor type II (MISRII) by administering to a subject a composition comprising a recombinant human MIS protein. Another aspect of the present invention relates to methods to lower plasma androgen levels in a subject, and/or for the treatment of a subject with a disease characterized by excess androgen. Another aspect provides pharmaceutical compositions and kits and methods for use comprising a recombinant human MIS protein. Another aspect of the present invention relates to methods to decrease the dose of a chemotherapeutic agent by administering the chemotherapeutic agent with the recombinant MIS protein that lowers the effective dose of the chemotherapeutic agent.


Find Patent Forward Citations

Loading…